Author

Tubić, Biljana

University of Banja Luka, Faculty of Medicine, Department of Pharmacy; Agency for medicines and - Cited by 235 - In silico/In vitro biopharmaceutical characterizatio of the new pharmaceutical substances (Moleckular Docking study - PAMPA test

Biography

Dr. Tubic Biljana completed all his studies from University of Belgrade in the field of pharmacy. He started working as an assistant  in 1999 in the University of Banja Luka in the Department of Pharmacy and now is an Associate Professor there. Also worked as a pharmacist where the role was to handle all the pharmaceutical regulatory system of medicines, and - medicinal chemistry (development and validation of analytical and bio analytical methods, in silico and in vitro biocharacterization of pharmaceutical substances). The research interests are Herbal Medicine, Medicinal Plants, Phytochemicals, Natural Product Drug Discovery, Phytochemical Analysis, and Antioxidant Activity.
Title
Cited by
Year
Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization
R Suručić, B Tubić, MP Stojiljković, DM Djuric, M Travar, M Grabež, ...Molecular and cellular biochemistry 476, 1179-1193, 2021202
59
2021
The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for …
B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, ...Frontiers in public health 9, 671961, 2021202
35
2021
Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications
N Miljković, B Godman, M Kovačević, P Polidori, L Tzimis, T Hoppe-Tichy, ...Frontiers in pharmacology 11, 357, 2020202
34
2020
Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 Receptor: In silico and in vitro studies
R Suručić, M Travar, M Petković, B Tubić, MP Stojiljković, M Grabež, ...Bioorganic chemistry 114, 105145, 2021202
31
2021
Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological …
U Glamočlija, B Tubić, M Kondža, A Zolak, N GrubišaCroatian Medical Journal 59 (3), 124-131, 2018201
16
2018
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: findings and implications
B Tubic, V Marković-Peković, S Jungić, E Allocati, B GodmanMedicine Access@ Point of Care 5, 239920262027692, 2021202
11
2021
The role of biomarkers in the development of novel cancer therapies
S Jungić, B Tubić, T SkrepnikDrug Metabolism and Drug Interactions 27 (2), 9-99, 2012201
8
2012
Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications
B Godman, M Wladysiuk, S McTaggart, A Kurdi, E Allocati, M Jakovljevic, ...BioMed research international 2021, 2021202
8
2021
Challenges and opportunities with routinely collected data on the utilization of cancer medicines. Perspectives from health authority personnel across 18 European countries
A Pisana, B Wettermark, A Kurdi, B Tubic, C Pontes, C Zara, E Van Ganse, ...Frontiers in pharmacology 13, 83556, 2022202
7
2022
Dissolution profile of nimesulide from pharmaceutical preparations for oral use
B Tubić, A Uzunović, S Pilipović, Ž GagićActa Chimica Slovenica 63 (1), 193-199, 2016201
7
2016
Highly sensitive UHPLC—MS/MS method for quantification of ethylenediamine-N,N′-di-2-(3-cyclohexyl) propanoic acid derivatives in mouse serum
BK Tubić, BD Marković, SS Vladimirov, SM Ristić, BM Ivković, MM Savić, ...Acta Chromatographica 29 (2), 23-22, 2017201
5
2017
Simulataneous determination of nimesulide and its impurities in pharmaceutical formulations by reversed-phase high-performance liquid chromatography
B Tubić, B Ivković, M Zečević, S VladimirovActa Chimica Slovenica 54 (), 58-590, 2007200
3
2007
Adjuvant treatment of the salivary duct carcinoma with Her2 overexpression
Adjuvant treatment of the salivary duct carcinoma with Her overexpressionJ Berendika, S Jungić, B Tubić, G Malčić Kecman, I Rakita, Z Gojković, ...Case Reports in Oncology 14 (1), 610-615, 010
2
2021
Prediction of in vivo Bioavailibility by in vitro Characterization of Ethylenediamine Dipropanoic Acid Derivatives with Cytotoxic Activity
BK Tubić, SS Vladimirov, BD Marković, T SaboActa Chimica Slovenica 65 (1), 59-64, 01801
2
2018
Biosimilars are essential for sustainable healthcare systems across Europe; however, key challenges remain as seen with biosimilars for long-acting insulin analogues
B Godman, B Tubić, E Allocati, M Wladysiuk, S McTaggart, A Kurdi, ...Journal of Applied Pharmaceutical Science 1 (3), 55-7, 0
2
2022
The role of generics and biosimilars in the availability of medicines–challenges of similarity
B TubićArchives of Pharmacy 72 (Suppl. 4), S88-S89, 2022202
1
2022
Regulatory aspects of biological medicines in Bosnia and Herzegovina
B Tubić, S JungićBosnian Journal of Basic Medical Sciences 22 (4), 5, 2022202
1
2022
Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: single-center study
S Jungić, B Tubić, J Berendika, Z Gojković, I Rakita, M Vještica, ...Vojnosanitetski pregled 79 (08), 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=o244IVQAAAAJ&hl=sr

Cited by
Citations 235
h-index 8
i10-index 6
Recommended Journals
Open Access Journals